Fair balance and safety information
In the US, promotional materials generally need to present risks alongside benefits, with important safety information where required.
Pharmaceutical and biotech marketing happens inside medical, legal and regulatory review, with different rules for healthcare professionals and the public in every market. We plan content and campaigns that respect that process from the start.
Healthcare organizations we've worked with




Common priorities
Understanding pharma / biotech marketing
Every claim usually needs a reference, every asset passes through review, and timelines have to allow for it.
Brand, medical affairs and commercial teams work together, with medical, legal and regulatory (MLR) review approving materials before use. Audiences include specialists, primary care physicians, pharmacists, payers and, where permitted, patients and caregivers. Earlier-stage biotech companies often focus on disease awareness, investor communication and clinical trial recruitment.
The rules differ sharply by country. In the US, the FDA oversees prescription drug promotion, and direct-to-consumer advertising is allowed with fair balance requirements. In Canada, the UK and Australia, advertising prescription medicines to the public is generally prohibited, so campaigns focus on healthcare professionals and unbranded disease awareness.
Priorities & opportunities
Educational content, congress support and HCP-focused digital campaigns built on referenced claims.
Disease education helps patients recognize symptoms and talk to their doctor, especially where branded promotion is restricted.
Clear, ethics-approved recruitment content and campaigns help eligible participants find studies.
Building MLR stages into schedules avoids last-minute delays before launches and congresses.
How DocWin can help
Strategy call
Talk through your buyers, channels and review requirements with our strategists. Prefer to start with data? Request a free audit of your current presence.
Rules & sensitivities
In the US, promotional materials generally need to present risks alongside benefits, with important safety information where required.
In Canada, the UK and Australia, prescription medicines generally can't be advertised to the public, which changes channel and message choices.
Comments and messages on digital channels can include reports of side effects. Monitoring and reporting processes need to be agreed before channels go live.
This isn't legal advice. Rules differ by country, state and province, so confirm specific requirements with your own legal or compliance adviser.
A tailored approach
We start with the indication, audiences, markets and the approved claims available.
Timelines include MLR rounds, and content is prepared with references for efficient review.
Assets are created for each audience and adapted for each market's rules.
Channels are monitored, with agreed processes for adverse event reporting.
“DocWin helped me set up a professional website for my clinic and improve my local online visibility. The team was clear about what is allowed in medical marketing and avoided any misleading claims. The process was smooth and well-organized.”
Dr. Gregory SullivanRadiologist, DocWin client10+ practicing doctors on our review panel.
Every DocWin client is paired with a practicing doctor who reviews patient-facing content for medical accuracy and responsible communication.
Related industries
Yes. We prepare content with claims linked to references and annotations that make review more efficient, and we plan time for review rounds.
Yes. We can build HCP portals and gated content with appropriate access controls, alongside public disease awareness materials.
Yes. We create recruitment pages and campaigns using ethics-approved materials, with privacy-aware screening forms.
We agree a monitoring and escalation process with your pharmacovigilance team before any channel goes live.
Pharma marketing involves prescription and regulated medicines with MLR review and strict promotional rules. Nutraceutical brands sell consumer products under different claim rules.
150%
Average patient increase

4.9/5 client ratingclient satisfaction rating
Book a strategy call to discuss your product, markets and review process, and how DocWin could support your team.